Quebec Man Crowdfunds His Way to Remission

A Quebec man whose story of marriage and cancer diagnosis led to crowd-funding almost $700,000 is in full remission, according to a post on his Facebook page.

Matthew Schreindorfer of Laval, Que., and his wife, Katia Luciani, began an online crowd-funding campaign in February after he learned the only chance at surviving his acute lymphoblastic leukemia would be to participate in a clinical trial that cost $675,000.

"I have some incredible news to tell everyone," he posted on Facebook. "I did my bone marrow biopsy on Tuesday, and my oncologist announced to us yesterday that I am in complete remission. There is absolutely not one cancer cell left."

Schreindorfer was diagnosed with the disease last summer at the age of 24 after he returned from his honeymoon.

The crowd-funding campaign raised an astonishing $740,000 in just two months – money that was used to pay for experimental T-cell treatment, known as CAR-T cell treatment, at Memorial Sloan Kettering Cancer Center in New York, as well as accommodations.

"You have all helped save my life with your encouragements, donations and support, and I will forever be grateful! I will never forget this moment in my life where so many strangers came together to give me a second chance at life! Thank you from the bottom of my heart to my family, friends and saviors out there!"

Schreindorfer and his wife will remain in New York for another two weeks before they are expected to return to Laval.

Source: CBC

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap